Chu S - Search Results

1

MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.

Wang LS, Li L, Li L, Chu S, Shiang KD, Li M, Sun HY, Xu J, Xiao FJ, Sun G, Rossi JJ, Ho Y, Bhatia R. Wang LS, et al. Among authors: chu s. Blood. 2015 Feb 19;125(8):1302-13. doi: 10.1182/blood-2014-06-581926. Epub 2014 Dec 16. Blood. 2015. PMID: 25515961 Free PMC article.

2

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Chu S, Holtz M, Gupta M, Bhatia R. Chu S, et al. Blood. 2004 Apr 15;103(8):3167-74. doi: 10.1182/blood-2003-04-1271. Epub 2003 Dec 11. Blood. 2004. PMID: 15070699 Free article.

3

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Chu S, et al. Blood. 2005 Mar 1;105(5):2093-8. doi: 10.1182/blood-2004-03-1114. Epub 2004 Sep 2. Blood. 2005. PMID: 15345592 Free article.

4

Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.

Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Modi H, et al. Among authors: chu s. Blood. 2007 Jun 15;109(12):5411-21. doi: 10.1182/blood-2006-06-032490. Epub 2007 Mar 8. Blood. 2007. PMID: 17347407 Free PMC article.

5

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD, Snyder DS, Huettner CS, Shultz L, Holyoake T, Bhatia R. Zhang B, et al. Among authors: chu s. Cancer Cell. 2010 May 18;17(5):427-42. doi: 10.1016/j.ccr.2010.03.011. Cancer Cell. 2010. PMID: 20478526 Free PMC article.

6

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, Bhatia R. Chu S, et al. Blood. 2011 Nov 17;118(20):5565-72. doi: 10.1182/blood-2010-12-327437. Epub 2011 Sep 19. Blood. 2011. PMID: 21931114 Free PMC article.

7

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.

Zhang B, Chu S, Agarwal P, Campbell VL, Hopcroft L, Jørgensen HG, Lin A, Gaal K, Holyoake TL, Bhatia R. Zhang B, et al. Among authors: chu s. Blood. 2016 Dec 8;128(23):2671-2682. doi: 10.1182/blood-2015-11-679928. Epub 2016 Sep 12. Blood. 2016. PMID: 27621307 Free PMC article.

8

Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Chu S, McDonald T, Bhatia R. Chu S, et al. Leukemia. 2010 Apr;24(4):779-87. doi: 10.1038/leu.2010.24. Epub 2010 Mar 4. Leukemia. 2010. PMID: 20200561 Free PMC article.

9

Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells.

Modi H, Li L, Chu S, Rossi J, Yee JK, Bhatia R. Modi H, et al. Among authors: chu s. Leukemia. 2011 Feb;25(2):305-12. doi: 10.1038/leu.2010.257. Epub 2010 Nov 12. Leukemia. 2011. PMID: 21072043 Free PMC article.

10

BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.

Chu S, Li L, Singh H, Bhatia R. Chu S, et al. Cancer Res. 2007 Jul 15;67(14):7045-53. doi: 10.1158/0008-5472.CAN-06-4312. Cancer Res. 2007. PMID: 17638918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,723 results

Search Page

Filters